ClinicalTrials.gg
WithdrawnNCT07152730Updated Nov 14, 2025

A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump

A Phase 1 interventional study of Lutrepulse in Amenorrhea, Fertility and Infertility, sponsored by Ferring Pharmaceuticals. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Ferring Pharmaceuticals · Phase 1, Interventional, and Treatment

Why this study was withdrawn
The decision to terminate development activities was based on business needs and unrelated to any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Enrollment
28th of 30
0 · median 37
Started
2025
with 3 others
Phase 1
3 of 43
none open now
Registered
42nd of 43
by date
Lead sponsor
2 of 43
Ferring Pharmaceuticals

Among the 43 studies in Amenorrhea with a site in United States, this one is the 28th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 in phase 1, and was the 42nd registered.

Amenorrhea

79 studies on the registry are indexed under Amenorrhea; 16 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

One of the Causes of Amenorrhea is hypothalamic amenorrhea, which is a deficiency in the amplitude and/or frequency of endogenous Gonadotropin-releasing hormone (GnRH) Pulses. The results of this leads to anovulation and cessation of the menstrual cycle. Pulsatile GnRH has been widely used in the United States (US), Canada, and Europe for almost 40 years in the treatment of primary hypothalamic amenorrhea. It has a favorable safety profile and a high degree of effectiveness in enabling ovulation and spontaneous pregnancy. At the moment there are no other GnRH products on the market, nor are there any other drugs marketed for induction of ovulation in women with primary hypothalamic amenorrhea in the US, creating a clear unmet medical need. The goal of this trial is to characterize the exposure variability of GnRH when administered via the OmniPod.

03

Conditions studied

  • Amenorrhea
  • Fertility
  • Infertility

Keywords

  • Amenorrhea
  • Lutrepulse
  • Fertility
  • OmniPod
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female subjects 18 to 40 years old (both included).
  2. (BMI) between 18 and 30 kg/m2 (both included).
  3. Regular menstrual cycles of 24 to 35 days (both included).

Exclusion criteria

Exclusion Criteria

  1. Any medical condition, which in the judgment of the investigator, may interfere with the absorption, distribution, metabolism, or excretion of gonadotropin-releasing hormone (GnRH).
  2. Use of any hormonal , growth hormone, insulin or thyroid hormone replacement therapy 30 days prior to dosing in this trial.
  3. Previously known or suspected to GnRH.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group A (single dose)

    Single-dose (1 pulse) LUTREPULSE Omnipod 20ug/pulse

    Drug: Lutrepulse

  • Experimental
    Group B (multiple doses)

    Part 1 - Single dose (1 pulse) LUTREPULSE Omnipod 20ug/pulse Part 2 - multiple doses (6 pulse) LUTREPULSE Omnipod 20ug/pulse

    Drug: Lutrepulse

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: maximum observed plasma concentration from Part 1- Pulse 1

    Time frame: Up to 5 days

  2. AUC0-t: area under the concentration-time profile to the last quantified concentration from Part 1- Pulse 1

    Time frame: Up to 5 days

  3. AUC0-infinity: area under the concentration-time curve to infinity from Part 1- Pulse 1

    Time frame: Up to 5 days

Secondary outcomes

  1. tmax: time to maximum plasma concentration from Part 1- Pulse 1

    Time frame: Up to 5 days

  2. λz; terminal elimination rate constant from Part 1- Pulse 1

    Time frame: Up to 5 days

  3. t½; terminal elimination half-life from Part 1- Pulse 1

    Time frame: Up to 5 days

  4. Cmax: maximum observed plasma concentration from Part 2 - Pulse 6

    Time frame: Up to 4 days

  5. AUC0-t: area under the concentration-time profile to the last quantified concentration from Part 2 - Pulse 6

    Time frame: Up to 4 days

  6. AUCtau: area under the concentration-time profile at steady-state from Part 2 - Pulse 6

    Time frame: Up to 4 days

  7. tmax: time to maximum plasma concentration from Part 2 - Pulse 6

    Time frame: Up to 4 days

  8. λz; terminal elimination rate constant from Part 2 - Pulse 6

    Time frame: Up to 4 days

  9. t½; terminal elimination half-life from Part 2 - Pulse 6

    Time frame: Up to 4 days

07

Study locations

1 site
  • Ferring Investigational Site
    Miami, Florida 33172, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Oct 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 3, 2025
StartActual
Sep 12, 2025
Primary completionActual
Oct 29, 2025
CompletionActual
Oct 29, 2025
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07152730
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Sep 12, 2025
Primary completion
Oct 29, 2025
Completion
Oct 29, 2025
Last update
Nov 14, 2025

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gonadotropin-Releasing Hormone

Start the discussion